Sentences with phrase «of cell replacement therapies»
Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes
http://viacyte.com/
There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.
Our research goal is to understand the molecular and cellular events required for pancreatic β - cell regeneration, and apply this knowledge towards the development of cell replacement therapies for diabetes.
For the first time, researchers demonstrate long term success of a cell replacement therapy using autologous induced pluripotent stem cell derivatives
The initial phase of clinical investigation is focusing on the safety of the cell replacement therapy combination products in patients.
Not exact matches
«This research has broad impact, because by deepening our understanding of cell reprogramming we have the potential to improve disease modeling and the generation of better sources of patient - specific specialized cells suitable for replacement therapy,» said Plath.
Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.
These cells, in turn, instruct factor - VIII — specific immune cells to become tolerant to the coagulation protein, resulting in suppression of misdirected antibody responses to the replacement therapy — all without affecting the rest of the immune system.
HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.
But for cell replacement therapy to realize its potential, I anticipate that scientists must solve the developmental code, the set of rules that govern the formation of tissues, organs, and beings from the original single cell — the zygote.
«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.
An EU - funded research project («HumEn»), in which Lickert and his team are participating, shall provide further insights in the field of beta - cell replacement therapy.
With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes.
Our long - term goal, therefore, is to explore the potential to genetically disrupt both ccr5 and cxcr4 for cell replacement therapies in HIV infected individuals, and in the case of cxcr4 do so in a way that specifically targets CXCR4 on T cells and not the many other cell types on which it is expressed.
«The loss of insulin - producing beta cells leads to type 1 diabetes, making it an ideal target for cell replacement therapy,» said James Shapiro, MD, PhD, FRCSC, Director of the Clinical Islet Transplant Program, University of Alberta.
Regardless of the targeted organ for cell replacement or regeneration, the shared challenges in cell therapies for diabetes such as transplant procedure and immune rejection will be well - served by the collective expertise within CCTD.
Cell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etCell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etc.).
Early clinical evidence with the PEC - Encap product supports the potential of the replacement cell therapy approach.
«ViaCyte was the first to differentiate human stem cells into glucose - responsive, insulin - producing cells, and now we are running the first and only clinical trials of stem cell - derived islet replacement therapies for type 1 diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.
The cells generated in the Zeng lab may not only provide a potential unlimited source for cell replacement therapy for Parkinson's disease, but also offer an unprecedented opportunity to develop screening models for assessing small molecule drugs and to clarify the mechanisms of disease.
SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.
SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
The third and final day of the 2016 Huntington's Disease Therapeutics Conference brings updates on cell replacement therapies including stem cells; and new ways to assess and model the progression of HD to help understand it and run crucial clinical trials.
Comparisons of genetically matched human pluripotent stem cells reveals that somatic cell nuclear transfer is the ideal means of generating cells for replacement therapy
Basically what was happening when you use a hematopoietic stem cell to correct an inherited metabolic disease is that through engraftment of that cell you are allowing that cell to become the replacement source for the missing enzyme or other factor - almost like a cellular form of gene therapy or, as I call it, «poor man's gene therapy».
Scientists publishing in the journal Cell Stem Cell have reported the production of functional human oocytes from discarded genetic material, a process which they suggest could one day assist in fertility treatment or mitochondrial replacement therapy.
The title of the paper is «The Ideal Gene Delivery Vector: Chromallocytes, Cell Repair Nanorobots for Chromosome Replacement Therapy» and it is currently in press at the peer - reviewed Journal of Evolution and Technology (and is soon to be available online).
While many important developments impacted the field, two that garnered significant public, political and scientific attention in 2016 were the proliferation of clinics using unproven stem cell «therapies,» and the steps forward in therapeutic modification of human oocytes (unfertilized eggs) through a process called mitochondrial replacement therapy (MRT).
«These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing novel cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
JDRF and ViaCyte Announce Support for Development of PEC - Direct Cell Replacement Therapy for Type 1 Diabetes
SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.
In addition, we use our expertise to facilitate the development of functionally mature beta cells from embryonic stem cells for cell replacement therapies of type 1 diabetes.
SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.
In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.
Cell replacement therapies require clinically safe stem cells that can be used to generate many (possibly all) types of cells.
The first - in - human STEP ONE * trial is evaluating the safety and efficacy of ViaCyte's PEC - Encap (a.k.a. VC - 01 ™) product candidate, a stem cell - derived, encapsulated cell replacement therapy.
San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.
ViaCyte's VC - 01 ™ product candidate, a first - in - class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC - 01 Combination Product in Type One Diabetes.
San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:
«We are grateful to CIRM and the citizens of California for their continued support of our potentially transformative stem cell - derived, cell replacement therapies for diabetes,» said Paul Laikind, Ph.D., President and CEO of ViaCyte.
Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem cell sources for the derivation of specific types of clinically relevant neuronal or glial cells, for their use in disease modelling and drug discovery platforms, and towards refining their efficacy for future cell replacement - based therapy.
With the STEP ONE trial underway, and the addition of W. L. Gore & Associates as collaborators to optimize the Encaptra ® cell delivery system, ViaCyte felt that the PEC - Direct approach might be the most rapid way to get the invaluable PEC - 01 cell replacement therapy to those who need it most.
The new iPS cells generated using novel methods may represent biomedically - and clinically - ideal cells, providing potential platforms for studying human disease mechanisms and achieving the long - term goal of personalized cell - replacement therapy.
SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.
Partial clinical hold on high dose SGT - 001 resolved, additional information requested on full clinical hold NIH grant will further development of replacement beta cells for type 1 and type 2 diabetes New trial will assess MSCs to improve heart function in heart failure patients ReNeuron wins grant for retinal cell therapy development
Information on the clinical testing of ViaCyte's implantable cell replacement therapies can be found at Clinicaltrials.gov.
«JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.
The WFIRM research team is working to engineer replacement tissues and organs and develop healing cell therapies for more than 30 different areas of the body.
A number of treatments exist, including enzyme replacement therapy and hematopoietic stem cell transplantation, but efficacy depends upon diagnosing the disease and its specific form as early as possible.